Francesc E. Borràs
Autonomous University of Barcelona
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Francesc E. Borràs.
Journal of extracellular vesicles | 2015
María Yáñez-Mó; Pia Siljander; Zoraida Andreu; Apolonija Bedina Zavec; Francesc E. Borràs; Edit I. Buzás; Krisztina Buzás; Enriqueta Casal; Francesco Cappello; Joana Carvalho; Eva Colas; Anabela Cordeiro da Silva; Stefano Fais; Juan M. Falcon-Perez; Irene M. Ghobrial; Bernd Giebel; Mario Gimona; Michael W. Graner; Ihsan Gursel; Mayda Gursel; Niels H. H. Heegaard; An Hendrix; Peter Kierulf; Katsutoshi Kokubun; Maja Kosanović; Veronika Kralj-Iglič; Eva-Maria Krämer-Albers; Saara Laitinen; Cecilia Lässer; Thomas Lener
In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and nucleic acids, thereby influencing various physiological and pathological functions of both recipient and parent cells. While intensive investigation has targeted the role of EVs in different pathological processes, for example, in cancer and autoimmune diseases, the EV-mediated maintenance of homeostasis and the regulation of physiological functions have remained less explored. Here, we provide a comprehensive overview of the current understanding of the physiological roles of EVs, which has been written by crowd-sourcing, drawing on the unique EV expertise of academia-based scientists, clinicians and industry based in 27 European countries, the United States and Australia. This review is intended to be of relevance to both researchers already working on EV biology and to newcomers who will encounter this universal cell biological system. Therefore, here we address the molecular contents and functions of EVs in various tissues and body fluids from cell systems to organs. We also review the physiological mechanisms of EVs in bacteria, lower eukaryotes and plants to highlight the functional uniformity of this emerging communication system.
PLOS Biology | 2012
Hina Kalra; Richard J. Simpson; Hong Ji; Elena Aikawa; Peter Altevogt; Philip W. Askenase; Vincent C. Bond; Francesc E. Borràs; Xandra O. Breakefield; Vivian Budnik; Edit I. Buzás; Giovanni Camussi; Aled Clayton; Emanuele Cocucci; Juan M. Falcon-Perez; Susanne Gabrielsson; Yong Song Gho; Dwijendra K. Gupta; H. C. Harsha; An Hendrix; Andrew F. Hill; Jameel M. Inal; Guido Jenster; Eva-Maria Krämer-Albers; Sai Kiang Lim; Alicia Llorente; Jan Lötvall; Antonio Marcilla; Lucia Mincheva-Nilsson; Irina Nazarenko
Vesiclepedia is a community-annotated compendium of molecular data on extracellular vesicles.
Blood | 2009
Nuria Izquierdo-Useros; Mar Naranjo-Gómez; Jacob Archer; Steven C. Hatch; Itziar Erkizia; Julià Blanco; Francesc E. Borràs; Maria C. Puertas; John H. Connor; María Teresa Fernández-Figueras; Landon Moore; Bonaventura Clotet; Suryaram Gummuluru; Javier Martinez-Picado
Exosomes are secreted cellular vesicles that can be internalized by dendritic cells (DCs), contributing to antigen-specific naive CD4(+) T-cell activation. Here, we demonstrate that human immunodeficiency virus type 1 (HIV-1) can exploit this exosome antigen-dissemination pathway intrinsic to mature DCs (mDCs) for mediating trans-infection of T lymphocytes. Capture of HIV-1, HIV-1 Gag-enhanced green fluorescent protein (eGFP) viral-like particles (VLPs), and exosomes by DCs was up-regulated upon maturation, resulting in localization within a CD81(+) compartment. Uptake of VLPs or exosomes could be inhibited by a challenge with either particle, suggesting that the expression of common determinant(s) on VLP or exosome surface is necessary for internalization by mDCs. Capture by mDCs was insensitive to proteolysis but blocked when virus, VLPs, or exosomes were produced from cells treated with sphingolipid biosynthesis inhibitors that modulate the lipid composition of the budding particles. Finally, VLPs and exosomes captured by mDCs were transmitted to T lymphocytes in an envelope glycoprotein-independent manner, underscoring a new potential viral dissemination pathway.
PLOS Pathogens | 2010
Nuria Izquierdo-Useros; Mar Naranjo-Gómez; Itziar Erkizia; Maria C. Puertas; Francesc E. Borràs; Julià Blanco; Javier Martinez-Picado
Exosomes are secreted cellular vesicles that can induce specific CD4+ T cell responses in vivo when they interact with competent antigen-presenting cells like mature dendritic cells (mDCs). The Trojan exosome hypothesis proposes that retroviruses can take advantage of the cell-encoded intercellular vesicle traffic and exosome exchange pathway, moving between cells in the absence of fusion events in search of adequate target cells. Here, we discuss recent data supporting this hypothesis, which further explains how DCs can capture and internalize retroviruses like HIV-1 in the absence of fusion events, leading to the productive infection of interacting CD4+ T cells and contributing to viral spread through a mechanism known as trans-infection. We suggest that HIV-1 can exploit an exosome antigen-dissemination pathway intrinsic to mDCs, allowing viral internalization and final trans-infection of CD4+ T cells. In contrast to previous reports that focus on the ability of immature DCs to capture HIV in the mucosa, this review emphasizes the outstanding role that mature DCs could have promoting trans-infection in the lymph node, underscoring a new potential viral dissemination pathway.
Bioinformatics | 2015
Dae-Kyum Kim; Jaewook Lee; Sae Rom Kim; Dong Sic Choi; Yae Jin Yoon; Ji Hyun Kim; Gyeongyun Go; Dinh Nhung; Kahye Hong; Su Chul Jang; Si-Hyun Kim; Kyong-Su Park; Oh Youn Kim; Hyun Taek Park; Jihye Seo; Elena Aikawa; Monika Baj-Krzyworzeka; Bas W. M. van Balkom; Mattias Belting; Lionel Blanc; Vincent C. Bond; Antonella Bongiovanni; Francesc E. Borràs; Luc Buée; Edit I. Buzás; Lesley Cheng; Aled Clayton; Emanuele Cocucci; Charles S. Dela Cruz; Dominic M. Desiderio
MOTIVATION Extracellular vesicles (EVs) are spherical bilayered proteolipids, harboring various bioactive molecules. Due to the complexity of the vesicular nomenclatures and components, online searches for EV-related publications and vesicular components are currently challenging. RESULTS We present an improved version of EVpedia, a public database for EVs research. This community web portal contains a database of publications and vesicular components, identification of orthologous vesicular components, bioinformatic tools and a personalized function. EVpedia includes 6879 publications, 172 080 vesicular components from 263 high-throughput datasets, and has been accessed more than 65 000 times from more than 750 cities. In addition, about 350 members from 73 international research groups have participated in developing EVpedia. This free web-based database might serve as a useful resource to stimulate the emerging field of EV research. AVAILABILITY AND IMPLEMENTATION The web site was implemented in PHP, Java, MySQL and Apache, and is freely available at http://evpedia.info.
ACS Nano | 2016
Stefano Fais; Lorraine O'Driscoll; Francesc E. Borràs; Edit I. Buzás; Giovanni Camussi; Francesco Cappello; Joana Carvalho; Anabela Cordeiro da Silva; Hernando A. del Portillo; Samir El Andaloussi; Tanja Ficko Trček; Roberto Furlan; An Hendrix; Ihsan Gursel; Veronika Kralj-Iglič; Bertrand Kaeffer; Maja Kosanović; Marilena E. Lekka; Georg Lipps; Mariantonia Logozzi; Antonio Marcilla; Marei Sammar; Alicia Llorente; Irina Nazarenko; Carla Oliveira; Gabriella Pocsfalvi; Lawrence Rajendran; Graça Raposo; Eva Rohde; Pia Siljander
Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.
Journal of Translational Medicine | 2011
Marisa Naranjo-Gomez; Dàlia Raïch-Regué; C Oñate; Laia Grau-López; Cristina Ramo-Tello; Ricardo Pujol-Borrell; Eva Martínez-Cáceres; Francesc E. Borràs
BackgroundThe use of tolerogenic DCs is a promising therapeutic strategy for transplantation and autoimmune disorders. Immunomodulatory DCs are primarily generated from monocytes (MDDCs) for in vitro experiments following protocols that fail to fulfil the strict regulatory rules of clinically applicable products. Here, we compared the efficacy of three different tolerance-inducing agents, dexamethasone, rapamycin and vitamin D3, on DC biology using GMP (Good Manufacturing Practice) or clinical grade reagents with the aim of defining their use for human cell therapy.MethodsTolerogenic MDDCs were generated by adding tolerogenic agents prior to the induction of maturation using TNF-α, IL-β and PGE2. We evaluated the effects of each agent on viability, efficiency of differentiation, phenotype, cytokine secretion and stability, the stimulatory capacity of tol-DCs and the T-cell profiles induced.ResultsDifferences relevant to therapeutic applicability were observed with the cellular products that were obtained. VitD3-induced tol-DCs exhibited a slightly reduced viability and yield compared to Dexa-and Rapa-tol-DCs. Phenotypically, while Dexa-and VitD3-tol-DCs were similar to immature DCs, Rapa-tol-DCs were not distinguishable from mature DCs. In addition, only Dexa-and moderately VitD3-tol-DCs exhibited IL-10 production. Interestingly, in all cases, the cytokine secretion profiles of tol-DCs were not modified by a subsequent TLR stimulation with LPS, indicating that all products had stable phenotypes. Functionally, clearly reduced alloantigen T cell proliferation was induced by tol-DCs obtained using any of these agent. Also, total interferon-gamma (IFN-γ) secretion by T cells stimulated with allogeneic tol-DCs was reduced in all three cases, but only T cells co-cultured with Rapa-tol-DCs showed impaired intracellular IFN-γ production. In addition, Rapa-DCs promoted CD4+ CD127 low/negative CD25high and Foxp3+ T cells.ConclusionsOur results demonstrate contrasting influences of different clinical-grade pharmacological agents on human tol-DC generation. This should be taken into account for decisions on the use of a specific agent for the appropriate cellular therapy in the context of a particular disease.
Journal of Virology | 2007
Nuria Izquierdo-Useros; Julià Blanco; Itziar Erkizia; María Teresa Fernández-Figueras; Francesc E. Borràs; Mar Naranjo-Gómez; Margarita Bofill; Lidia Ruiz; Bonaventura Clotet; Javier Martinez-Picado
ABSTRACT Dendritic cells (DCs) are specialized antigen-presenting cells. However, DCs exposed to human immunodeficiency virus type 1 (HIV-1) are also able to transmit a vigorous cytopathic infection to CD4+ T cells, a process that has been frequently related to the ability of DC-SIGN to bind HIV-1 envelope glycoproteins. The maturation of DCs can increase the efficiency of HIV-1 transmission through trans infection. We aimed to comparatively study the effect of maturation in monocyte-derived DCs (MDDCs) and blood-derived myeloid DCs during the HIV-1 capture process. In vitro capture and transmission of envelope-pseudotyped HIV-1 and its homologous replication-competent virus to susceptible target cells were assessed by p24gag detection, luciferase activity, and both confocal and electron microscopy. Maturation of MDDCs or myeloid DCs enhanced the active capture of HIV-1 in a DC-SIGN- and viral envelope glycoprotein-independent manner, increasing the life span of trapped virus. Moreover, higher viral transmission of mature DCs to CD4+ T cells was highly dependent on active viral capture, a process mediated through cholesterol-enriched domains. Mature DCs concentrated captured virus in a single large vesicle staining for CD81 and CD63 tetraspanins, while immature DCs lacked these structures, suggesting different intracellular trafficking processes. These observations help to explain the greater ability of mature DCs to transfer HIV-1 to T lymphocytes, a process that can potentially contribute to the viral dissemination at lymph nodes in vivo, where viral replication takes place and there is a continuous interaction between susceptible T cells and mature DCs.
Immunology | 2009
Laila Darwich; Gemma Coma; Ruth Peña; Rocío Bellido; Ester J. J. Blanco; José A. Esté; Francesc E. Borràs; Bonaventura Clotet; Lidia Ruiz; Antoni Rosell; Felipe Andreo; R. Michael E. Parkhouse; Margarita Bofill
The interferon (IFN)‐γ component of the immune response plays an essential role in combating infectious and non‐infectious diseases. Induction of IFN‐γ secretion by human T and natural killer (NK) cells through synergistic costimulation with interleukin (IL)‐12 and IL‐18 in the adaptive immune responses against pathogens is well established, but induction of similar activity in macrophages is still controversial, with doubts largely focusing on contamination of macrophages with NK or T cells in the relevant experiments. The possible contribution of macrophages to the IFN response is, however, an important factor relevant to the pathogenesis of many diseases. To resolve this issue, we analysed the production of IFN‐γ at the single‐cell level by immunohistochemistry and by enzyme‐linked immunosorbent spot (ELISPOT) analysis and unequivocally demonstrated that human macrophages derived from monocytes in vitro through stimulation with a combination of IL‐12 and IL‐18 or with macrophage colony‐stimulating factor (M‐CSF) were able to produce IFN‐γ when further stimulated with a combination of IL‐12 and IL‐18. In addition, naturally activated alveolar macrophages immediately secreted IFN‐γ upon treatment with IL‐12 and IL‐18. Therefore, human macrophages in addition to lymphoid cells contribute to the IFN‐γ response, providing another link between the innate and acquired immune responses.
European Journal of Immunology | 2012
Dàlia Raϊch-Regué; Laia Grau-López; Mar Naranjo-Gómez; Cristina Ramo-Tello; Ricardo Pujol-Borrell; Eva Martínez-Cáceres; Francesc E. Borràs
Multiple sclerosis (MS) is a chronic demyelinating autoimmune disease of the central nervous system. Current therapies decrease the frequency of relapses and limit, to some extent, but do not prevent disease progression. Hence, new therapeutic approaches that modify the natural course of MSneed to be identified. Tolerance induction to self‐antigens using monocyte‐derived dendritic cells (MDDCs) is a promising therapeutic strategy in autoimmunity. In this work, we sought to generate and characterize tolerogenic MDDCs (tolDCs) from relapsing‐remitting (RR) MSpatients, loaded with myelin peptides as specific antigen, with the aim of developing immunotherapeutics for MS. MDDCs were generated from both healthy‐blood donors and RR‐MSpatients, and MDDCmaturation was induced with a proinflammatory cytokine cocktail in the absence or presence of 1α,25‐dihydroxyvitamin‐D3, a tolerogenicity‐inducing agent. tolDCs were generated from monocytes of RR‐MSpatients as efficiently as from monocytes of healthy subjects. The RR‐MStolDCs expressed a stable semimature phenotype and an antiinflammatory profile as compared with untreated MDDCs. Importantly, myelin peptide‐loaded tolDCs induced stable antigen‐specific hyporesponsiveness in myelin‐reactive T cells from RR‐MS patients. These results suggest that myelin peptide‐loaded tolDCs may be a powerful tool for inducing myelin‐specific tolerance in RR‐MS patients.